How many spoonfuls of sugar? A Bert s-eye view of prescribing to manage blood sugar
|
|
- Marian Pope
- 5 years ago
- Views:
Transcription
1 How many spoonfuls of sugar? A Bert s-eye view of prescribing to manage blood sugar
2 What would Mary Poppins think? Please discuss
3 Some Sums Annual cost of diabetes (1 &2) in England = c. 24 billion Around 60% of this indirect loss of work, caring, etc. Around 40% direct healthcare cost to NHS = c. 10 billion [>90% type 2] = c. 10% TOTAL NHS budget Cost of prescriptions to manage blood sugar almost 10% of this
4 Multi-factorial management of Type 2 diabetes Education Smoking Lifestyle Diet & Activity Control blood pressure Everything else Control blood sugar Metformin Statins Individualised care of patients: based on evidence for each intervention
5 Management for type 2 diabetes: AIMS NICE Clinical Guideline 87; May 2009 Adopt a healthy lifestyle (stop smoking, exercise, weight management, etc.) Manage symptoms associated with having high blood glucose levels if patients have them Reduce risk of major life-threatening or disabling complications (heart attacks and stroke) Manage diabetic kidney damage, eye damage and nerve damage (foot disease, neuropathic pain, erectile-dysfunction, etc.) BUT targets for all the different aspects of this condition (BP, lipids, blood glucose etc.) can be demanding to reach Agree the priorities for care and targets for each aspect of management on an individualised patient basis as aggressive therapy of each aspect may not be appropriate for all.
6 Control blood sugar
7 North East CCGs total: Top 5 BNF sections in terms of current spend - April 2014 to December 2014 Actual Cost Rank BNF Section Current Previous Growth % 1 Corticosteroids (Respiratory) 34,813,707 33,098, Drugs Used In Diabetes 33,871,479 32,344, Analgesics 30,935,477 29,326, Antiepileptics 24,007,843 21,818, Bronchodilators 19,586,543 18,727, NHS North of England: Top 5 BNF sections in terms of current spend - April 2014 to December 2014 Actual Cost Rank BNF Section Current Previous Growth % 1 Drugs Used In Diabetes 176,759, ,287, Corticosteroids (Respiratory) 167,543, ,280, Analgesics 138,582, ,690, Antiepileptics 114,962, ,141, Bronchodilators 84,888,256 80,847, England: Top 5 BNF sections in terms of current spend - April 2014 to December 2014 Actual Cost Rank BNF Section Current Previous Growth % 1 Drugs Used In Diabetes 600,948, ,124, Corticosteroids (Respiratory) 490,872, ,079, Analgesics 377,086, ,921, Antiepileptics 339,559, ,530, Oral Nutrition 251,838, ,812,
8 HUGELY VARIABLE
9
10 Actual Cost per diabetic patient North East & Cumbria CCGs: Weighted prescribing cost of BNF 6.1: Drugs used in Diabetes - January 2012 to December Costs 38% more per patient to lower blood sugar levels in top spending CCG than in lowest spending CCG 1.2 million per annum EXTRA Cumbria Darlington Durham Dales, Easington & Sedgefield Gateshead Hartlepool & Stockton Newcastle North and East Newcastle West North Durham North Tyneside Northumberland South Tees South Tyneside Sunderland Teaching North East & Cumbria England North East & Cumbria Q4 1213Q1 1213Q2 1213Q3 1213Q4 1314Q1 1314Q2 1314Q3 1314Q4 1415Q1 1415Q2 1415Q3 Copyright RDTC 2015
11 Why such HUGE differences? Insulins analogue v human Newer drugs DPP4 inhibitors, GLP1 agonists, SGLT2 inhibitors Blood glucose testing strips
12 Insulin analogues
13 Insulins
14 Percentage (DDDs) Percentage (DDDs) Percentage (actual cost) Percentage (items) Spread? 110 North East & Cumbria CCGs: Analogue insulins as a % of all insulins - Actual cost - January 2012 to December 2014 North East & Cumbria CCGs: Insulins Detemir, Glargine and Degludec as a Percentage of All Long Acting and Intermediate Insulins (excluding biphasic insulins) - January 2012 to December Q4 1213Q1 1213Q2 1213Q3 1213Q4 1314Q1 1314Q2 1314Q3 1314Q4 1415Q1 1415Q2 1415Q3 Copyright RDTC 1112Q4 1213Q1 1213Q2 1213Q3 1213Q4 1314Q1 1314Q2 1314Q3 1314Q4 1415Q1 1415Q2 1415Q3 Copyright RDTC North East & Cumbria CCGs: Biphasic analogues as a % of all biphasic insulins - DDDs - January 2012 to December North East & Cumbria CCGs: Rapid acting analogues as a % of all short & rapid-acting insulins - DDDs - January 2012 to December Q4 1213Q1 1213Q2 1213Q3 1213Q4 1314Q1 1314Q2 1314Q3 1314Q4 1415Q1 1415Q2 1415Q3 Copyright RDTC Q4 1213Q1 1213Q2 1213Q3 1213Q4 1314Q1 1314Q2 1314Q3 1314Q4 1415Q1 1415Q2 1415Q3 Copyright RDTC 2015
15 Newer drugs Durham Dales, Easington & Sedgefield England Sunderland Teaching North Durham Darlington South Tees South Tyneside Hartlepool & Stockton North East & Cumbria Gateshead Cumbria Newcastle North and East Newcastle West North Tyneside Northumberland Actual Cost per diabetic patients Sitagliptin Liraglutide Exenatide Linagliptin Saxagliptin Dapagliflozin Lixisenatide Metformin Hydrochloride/Sitagliptin Vildagliptin Metformin Hydrochloride/Vildagliptin Others Copyright RDTC
16 Test Strips North East CCGs: Weighted prescribing cost of SMBG test strips - April 2014 to December 2014 Cumbria North Durham Newcastle North and East South Tees Newcastle West Sunderland Teaching North East & Cumbria North Tyneside Hartlepool & Stockton England South Tyneside Northumberland Durham Dales, Easington & Sedgefield Gateshead Darlington Actual Cost per diabetic patients Aviva (Reagent)_Strips Contour (Reagent)_Strips Contour Next (Reagent)_Strips Mobile (Reagent)_Strips OneTouch Ultra (Reagent)_Strips FreeStyle Lite (Reagent)_Strips GlucoRx Nexus (Reagent)_Strips Element (Reagent)_Strips FreeStyle Optium (Reagent)_Strips Compact (Reagent)_Strips Others Copyright RDTC
17 Photo finish?
18 % target met Spend per patient with diabetes vs HbA1c QOF (59mmol/mol_7%) North East and Cumbria CCGs: Prescribing cost per patient v Percentage with IFCC-HbA1c 59 mmol/mol or less in the last 12 months (DM 7) 78 Higher Target Achievement / Lower Cost Northumberland Newcastle North and East Darlington North Tyneside North East & Cumbria Newcastle West Cumbria Hartlepool & Stockton Gateshead South Tyneside Durham Dales, Easington & Sedgefield England North Durham South Tees Sunderland Teaching Lower Target Achievement / Higher Cost Actual Cost / diabetic patient Copyright RDTC
19 % target NOT met North East and Cumbria CCGs: Prescribing cost per patient v % with HbA1c above 75mmol/mol (9%) in the last 12 months [DM009 inverse] 14 More "treatment failures" / Higher Cost Gateshead 13 England 12 South Tyneside Sunderland Teaching North Tyneside Newcastle West Darlington Newcastle North and East North East & Cumbria Cumbria Hartlepool & Stockton South Tees North Durham Durham Dales, Easington & Sedgefield 9 Northumberland Fewer "treatment failures" / Lower Cost Actual Cost / diabetic patient Copyright RDTC 2015
20 Bed day excess vs expenditure on blood sugar 25% 20% 15% 10% 5% 0%
21 Multi-factorial management of Type 2 diabetes Education Smoking Lifestyle Diet & Activity Control blood pressure Everything else Control blood sugar Metformin Statins Individualised care of patients: based on evidence for each intervention
22 Control blood sugar
23 Relationship of reductions in cholesterol, blood pressure and HbA1c with improvements in CHD and CV outcomes Yudkin JS, et al. Diabetologia 2010;53: , MeReC Bulletin Vol. 21, No. 5, June 2011 Blood pressure lowering (reduction of 10/5mmHg) Cholesterol lowering (reduction of 1mmol/L) Intensive Blood glucose lowering (HbA1c reduction of 0.9%) (10mmol/mol) CV event Stroke CHD Number of events prevented per 1000 patients over 5 years
24 The Goldilocks effect Blood glucose lowering: not too little, not too much Currie CJ, et al. Lancet 2010;375:481 9, MeReC Rapid Review No Observational study: HbA1c of about 7.5% associated with lowest risk of all-cause mortality (increase above or decrease below this associated with greater risk) Adjusted hazard ratios for all-cause mortality by HbA1c deciles in people given metformin plus sulphonylurea (A) and insulin-based therapy (B) Metformin plus sulphonylurea Insulin-based therapy Vertical error bars show 95%CIs, horizontal bars show HbA1c range. Red circle = reference decile. *Truncated at lower quartile. Truncated at upper quartile
25 Law of diminishing returns: The absolute benefit decreases with each intervention, yet harms accumulate HARM BENEFIT Number of interventions
26 Reflection? At organisational level Do we know how we compare with others? Do we need to do something different? Insulins Newer drugs Blood glucose testing strips At individual prescriber level Do we need to pursue blood glucose target further? Can we get a better outcome another way? Am I making life more difficult polypharmacy Can I prescribe a less expensive drug and get the same effect?
27
New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationType 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options?
Patient decision aid Type 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options? nice.org.uk/guidance/ng28 Published: December 2015 About this decision
More informationRoot cause analysis of major lower limb amputations in diabetes 2013/14 at County Durham and Darlington Foundation Trust (CDDFT).
Root cause analysis of major lower limb amputations in diabetes 2013/14 at County Durham and Darlington Foundation Trust (CDDFT). By Dr Sara Haq GP Registrar, Durham and Tees Valley Deanery Diabetes Audit
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationImplementing the Optimal Lung Cancer Pathway
Implementing the Optimal Lung Cancer Pathway Climbing out of the too hard pile Liz Fuller -NCA clinical Lead Lung Sheron Robson -NCA programme manager Chris Tasker -CRUK Strategic GP Collaborating to improve
More informationDiabetes. Ref HSCW 024
Diabetes Ref HSCW 024 Why is it important? Diabetes is an increasingly common, life-long, progressive but largely preventable health condition affecting children and adults, causing a heavy burden on health
More informationDr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?
Dr Tahseen A. Chowdhury Royal London Hospital New Guidelines in Diabetes: NICE or Nasty? I have no conflicts of interest I do not undertake talks / advisory bodies / research for any pharma company Consultant
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationDr Katie Elliott CRUK strategic GP Macmillan GP with NE &C Learning disability Network Assistant Clinical Lead Northern Cancer Alliance
FIT for symptomatic patients Dr Katie Elliott CRUK strategic GP Macmillan GP with NE &C Learning disability Network Assistant Clinical Lead Northern Cancer Alliance AIMS Review National advice Consider
More informationClinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures
Clinical Guidelines Management of adult patients with diabetes undergoing endoscopic s Document Detail Document type Clinical Guideline Management of adult Patients with diabetes Undergoing Document name
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationDurham Research Online
Durham Research Online Deposited in DRO: 4 June 29 Version of attached file: Published Version Peer-review status of attached file: Peer-reviewed Citation for published item: Macknight, N. and Bailey,
More informationGUIDELINE FOR SELF MONITORING OF BLOOD GLUCOSE IN ADULTS WITH DIABETES
It is recognised that self- monitoring of blood glucose (SMBG) may have an important role to play for some patients with. It can allow individuals to see what impact particular behaviours, such as dietary
More informationDPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
THERAPY REVIEW DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes STEVE CHAPLIN SPL DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixeddose
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationNumber of people with diabetes
Written evidence from Diabetes UK DIABETES: THE BIGGEST HEALTH CHALLENGE OF OUR TIME A SYSTEM IN CRISIS 1. The Rising Tide of Diabetes and the Challenge for the NHS 2.1 Diabetes has become one of the biggest
More informationDIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0
Metformin DIABETES (1 of 5) Glucophage Glucophage XR ER $7 (500mg) $7 (500mg) $5 $5 500mg, 750mg only 500mg, 750mg only Sulfonylurea/Combinations Amaryl Glucotrol glimepiride glipizide $5 $5 Glucotrol
More informationSTEP 3: Add or Substitute with one of
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationInformation for Patients
Information for Patients Guidance for Diabetic Persons having an OGD or Bronchoscopy This guidance is provided to assist with your preparation for your endoscopic procedure. If you feel unclear about how
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationDiabetes Mellitus case studies. Jana Vinklerová
Diabetes Mellitus case studies Jana Vinklerová Definition of diabetes (metabolic disorder) Chronically raised blood glucose (hyperglycaemia) Insulin/Glucagon Insulin is responsible for lowering glucose
More informationThere have been important changes in diabetes care which may not be covered in undergraduate textbooks.
Diabetes Clinical update There have been important changes in diabetes care which may not be covered in undergraduate textbooks. Changes in the diagnosis of diabetes a) HbA1C Since 2011, World Health Organisation
More informationBarns Medical Practice Service Specification: Diabetes
Barns Medical Practice Service Specification: Diabetes DEVELOPED June 2017 REVIEW DATE June 2019 Introduction Diabetes mellitus is a life-long progressive condition that can be controlled but not cured.
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationrequesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group
requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group Canterbury and Coastal Clinical Consortium Group Medicine Management plans 2013/14
More informationDIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS)
Type 2 Diabetes DIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS) Clinical Guideline Self-monitoring of blood glucose (SMBG) should be considered but not be routinely offered for adults with type 2 diabetes
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationThe Cost of Alcohol to the North East Economy
The Cost of Alcohol to the North East Economy Introduction In 2008 The Centre for Public Health at Liverpool John Moore s University updated a 2003 Cabinet report 1 on the costs associated with alcohol
More informationDiabetes in England NHS Medical Directorate. Dr Rowan Hillson MBE National Clinical Director for Diabetes
Diabetes in England 2010 Dr Rowan Hillson MBE National Clinical Director for Diabetes I strongly believe that Everyone with diabetes deserves the highest standards of personalised diabetes care, no matter
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationTYP 2 DIABETES. Marc Donath
TYP 2 DIABETES Marc Donath Treatment of Typ 2 Diabetes GLP-1 Anti-IL-1β Insulin sulfonylureas Metformin UCP-1 IL-1β Sport SGLT2i Bariatric surgery Cardiomyocytes Control Glucose Dyntar et al. Diabetes
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More information3. Cardiovascular Disease?
Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationEstimated number of people with hypertension. Significantly higher than the. Proportion. diagnosed with. hypertension
Hypertension profile Background Diagnosis and control of hypertension in * This profile compares with data for, authorities in the South East region and the Office for National Statistics (ONS) group of
More informationFasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period
Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period Dr Ketan Dhatariya MBBS MSc MD MS FRCP Consultant in Diabetes and Endocrinology Norfolk and Norwich
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationDIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS)
DIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS) Type 2 Diabetes Clinical Guideline Self-monitoring of blood glucose (SMBG) should be considered but not routinely offered for adults with type 2 diabetes
More informationDiabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationinsulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S
insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed
More informationNational Diabetes Audit
National Diabetes Audit 2012-2013 Report 1: Care Processes and Treatment Targets Clinical Commissioning Group (CCG) / Local Health Board (LHB) Report Summary for NHS Wirral CCG (12F) Key findings about
More informationNational Diabetes Audit
National Diabetes Audit 2012-2013 Report 1: Care Processes and Treatment Targets Clinical Commissioning Group (CCG) / Local Health Board (LHB) Report Summary for NHS Bristol CCG (11H) Key findings about
More informationCommissioning Statement
Commissioning Statement Treatment/ device For the treatment of Commissioning position Flash Glucose Monitoring Systems (including Freestyle Libre ) Monitoring glucose levels in adults and children over
More informationGuidance on the Self-Monitoring of Blood Glucose in Adults with Diabetes
Introduction Guidance on the Self-Monitoring of Blood Glucose in Adults with Diabetes This guideline is designed to offer guidance for primary and secondary care on the use of selfmonitoring of blood glucose
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationThe York Diabetes Care Model
This Session The York Diabetes Care Model The annual review what s it for and how to do it How to make the diagnosis of diabetes and who to test Categorisation of diabetes at diagnosis Basics of Insulin
More informationDiabetes, Type 2 Management
CLINICAL GUIDELINE Diabetes, Type 2 Management A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised on the applicability
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationDiabetes Prevention & Management of Complications
Diabetes Prevention & Management of Complications Dr Ketan Dhatariya Consultant in Diabetes and Endocrinology NNUH The Planet is Changing IFCC (mmol/mol) = (current value (%) * 10.93) - 23.50 (reported
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationNICE Indicator Programme. Consultation on proposed amendments to current QOF indicators
NICE Indicator Programme Consultation on proposed amendments to current QOF s Consultation dates: 18 July to 1 August 2018 This document outlines proposed amendments to a small number of QOF s in the diabetes
More informationOutcomes of diabetes care in England and Wales. A summary of findings from the National Diabetes Audit : Complications and Mortality reports
Outcomes of diabetes care in England and Wales A summary of findings from the National Diabetes Audit 2015 16: Complications and Mortality reports About this report This report is for people with diabetes
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Type 2 diabetes: the management of type 2 diabetes (update)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Type 2 diabetes: the management of type 2 diabetes (update) 1.1 Short title Type 2 diabetes (update) 2 Background a) The National
More informationSummary of 2011/12 QOF indicator changes, points and thresholds
Summary of 2011/12 QOF indicator changes, points and thresholds Retirements 2010/11 QOF ID 2010/11 Indicator Wording Points Threshold CHD5 The percentage of patients with coronary heart disease whose notes
More informationDental health profile
Middlesbrough Sunderland Redcar and Cleveland Darlington Stockton-on-Tees NORTH EAST ENGLAND County Durham Northumberland South Tyneside North Tyneside Newcastle-upon- Tyne Gateshead Hartlepool Average
More information17/18 Threshold 18/19 Points 18/19. Points NO CHANGE NO CHANGE NO CHANGE
SUMMARY OF CHANGES TO QOF 2018/19 - ENGLAND 18-19 QOF005 KEY No change Retired/replaced Wording and/or timeframe change Point or threshold change Indicator ID change 17/18 QOF ID 18/19 QOF ID NICE ID Indicator
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationUpdate Diabetes Therapie. Marc Y Donath
Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPLEASE CHECK FULL SPECIFIC PRODUCT CHARACTERISTICS FOR MORE DETAILED AND CURRENT INFORMATION:
Metformin Standard tablets Modified-release tablets Metformin 1g sachets Metformin liquid 500mg/5ml (avoid use as expensive) < 2.00 5.32 for 56 tabs 500mg 13.16 for 60 sachets > 120 Ketoacidosis General
More informationArrange 3 Monthly Review Re-enforce LIFESTYLE advice and check DRUG COMPLIANCE at each visit Target HbA1c < 53mmol/mol
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationDiabetes and stroke. What is the link between diabetes and stroke? What is diabetes? What are the symptoms of diabetes?
Call the Stroke Helpline: 0303 3033 100 or email: info@stroke.org.uk Diabetes and stroke Diabetes is a lifelong condition that occurs when your body cannot regulate the amount of sugar in your blood. If
More informationType 2 Diabetes Recommended SMBG
Herefordshire Diabetes Guideline for Self-Monitoring Blood Glucose (SMBG) Type 2 Diabetes Recommended SMBG Diet controlled/ metformin only/ combination of metformin and pioglitazone/dpp4/sglt2 or GLP1
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationHypertension Profile. NHS High Weald Lewes Havens CCG. Background
NHS High Weald Lewes Havens Background Hypertension Profile Diagnosis and control of in NHS High Weald Lewes Havens * This profile compares NHS High Weald Lewes Havens with data for, a group of similar
More informationPOTENTIAL LINKAGES BETWEEN THE QUALITY AND OUTCOMES FRAMEWORK (QOF) AND THE NHS HEALTH CHECK
POTENTIAL LINKAGES BETWEEN THE QUALITY AND OUTCOMES FRAMEWORK (QOF) AND THE NHS HEALTH CHECK Author: CHARLOTTE SIMPSON, SPECIALTY REGISTAR PUBLIC HEALTH (ST3), CHESHIRE EAST COUNCIL/MERSEY DEANERY SUMMARY
More informationDiabetes and stroke. What is diabetes? What are the symptoms of diabetes? Stroke Helpline: Website: stroke.org.uk
Stroke Helpline: 0303 3033 100 Website: stroke.org.uk Diabetes is a condition caused by too much sugar in your blood. There are over three million people in the UK who have diabetes. If it s not controlled
More informationSUMMARY OF CHANGES TO QOF 2014/15 - ENGLAND CLINICAL
SUMMARY OF CHANGES TO QOF 20 - ENGLAND KEY No change Retired /or change Point or threshold change Funding transferred to enhanced services change QOF NICE CLINICAL Atrial Fibrilation (AF) AF001 AF001 -
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationNovel anti-diabetic therapies
Prof. Manfredi Rizzo, MD, PhD ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of Palermo, Italy & ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of South
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationPatient decision aid: Type 2 diabetes blood pressure control
Patient decision aid: Type 2 diabetes blood pressure control What this patient decision aid is for? This decision aid is intended to assist healthcare professionals in consultations with patients who have
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationMedicines Optimisation Team Standard Operating procedure for Alogliptin Audit:
Medicines Optimisation Team Standard Operating procedure for Alogliptin Audit: To review type 2 diabetic patients prescribed dipedtidylpeptidase-4 (DPP-4) inhibitors (linagliptin (Trajenta, saxagliptin
More informationSUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND CLINICAL
SUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND KEY No change Retired/replaced Wording and/or timeframe change Point or threshold change Indicator ID change 1/17 QOF ID 17/18 QOF ID NICE ID Indicator wording
More informationMeeting: Cancer Steering Group Date: 04/08/15
Meeting: Cancer Steering Group Date: 04/08/15 Time: 2:00pm Venue: Evolve Business Centre Present: Alison Featherstone, Network Manager, NHS England Roy McLachlan, Associate Director, NHS England Chris
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationFebruary 2016 DIABETES PHARMACY TEAMS MAKE A DIFFERENCE. Why am I here? Why are you here? Identifying people at risk. What can we do?
DIABETES PHARMACY TEAMS MAKE A DIFFERENCE Sallianne Kavanagh MRPharmS, MSc, IP Lead Pharmacist Diabetes and Endocrinology Sheffield Teaching Hospitals UKCPA Joint Chair Diabetes and Endocrinology Why am
More informationDr A Pokrajac MD MSc MRCP Consultant
Dr A Pokrajac MD MSc MRCP Consultant Onset at 5-15 years of T1DM Can be present at diagnosis of T2DM Detect in regular MA/Cr screening (2X first urine sample, no UTI, no other causes) Contributing Factors
More information